This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2040 Remove Compliance Remove Conditions Related Topics
Compliance Clinical Trials Epilepsy Chronic Pain Concentrates Data Consumption Treatment Cannabinoids Programs More Related Topics >
article thumbnail

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Cannabis Law Report

NOVEMBER 12, 2021

” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose. We recently announced a key milestone with the issuance of a method of use patent for ANEB-001, providing protection through 2040. Chief Executive Officer of Anebulo. “We

Pharmaceutical 52
Pharmaceutical Clinical Trials Business Research and Development 52
article thumbnail

Euro & UK Roundup: Czech Republic, Ireland, San Marino, UK

Cannabis Law Report

SEPTEMBER 28, 2019

Legislation passed last July allows a Consultant doctor to prescribe medicinal cannabis, but it is restricted to just three conditions. A symposium in Limerick has heard that the medical cannabis access programme here is too restrictive and needs to be extended to include people who suffer with chronic pain.

Epilepsy 40
Epilepsy Chronic Pain Medicine Pharmaceutical 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 24,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024